Klebs von den Lungen-6 (KL-6) is a high molecular weight mucin-like glycoprotein and is classified as human MUC1 mucin. It is highly expressed on regenerated type II alveolar cells. Higher serum levels of KL-6 were found in patients with various respiratory diseases, including ILD-type idiopathic interstitial pneumonia, collagen-vascular disease-associated interstitial pneumonia, hypersensitivity pneumonia, sarcoidosis, lung cancer and tuberculosis. The presence and severity of pulmonary fibrosis is also associated with elevated serum levels of KL-6. Creative BioMartBiomarker is capable to provide our customers with superior KL-6 detection service, various detection methods ensuring high sensitivity for detecting biomarkers in different samples with different concentrations.
Klebs von den Lungen-6 (KL-6)
KL-6 is a high molecular weight glycoprotein classified as human transmembrane MUC1. As a mucin, MUC1 protein can serve as a membrane receptor, consisting of the N-terminal subunit of MUC1 and the C-terminal subunit of MUC1, forming a stable non-covalent complex. On the plasma membrane, the extracellular domain of MUC1 can be shed into the lumen by proteolytic cleavage of the SEA domain. Another mechanism is proteolytic cleavage near the plasma membrane by the action of MT1-MMP or MMP14. Therefore, elevated MT1-MMP or MMP14 levels under pulmonary fibrosis conditions can mediate the release of the extracellular MUC1 domain (MUC1-N / KL-6). Serum KL-6 levels increase during acute IPF exacerbations. A continuous increase in serum KL-6 levels was associated with a predicted rapid decline in forced vital capacity (FVC), and further demonstrated higher KL-6 levels were associated with lower survival rates. Therefore, KL-6 can be used as a biomarker for disease activity and clinical outcome prediction of idiopathic pulmonary fibrosis (IPF), and KL-6 has been proven to be a reliable prognostic biomarker. IPF, a chronic progressive fibrosing interstitial pneumonia of unknown cause, occurs mainly in older adults. IPF biomarkers are important for predicting disease progression and treatment response, and for differential diagnosis.
Figure 1. Structure of mucin MUC1 (Ballester, B.; et al. 2019)
Application of KL-6
KL-6 serum levels can be used as a biomarker for disease activity and clinical outcome prediction of IPF, and KL-6 has been proven to be a reliable prognostic biomarker.
Our Advantages
- Guarantee high accuracy and sensitivity for KL-6 detection
- Ensure high repeatability of KL-6 detection
- Experienced biomarker detection technical team
- Strictly control each specific experimental step to ensure accurate and reliable test results in each sample
- Short turnaround time to accelerate your research
- More favorable prices in the biomarker testing service market can help reduce research costs
Detection Technologies
Samples
- Sample types: serum, plasma, cell culture supernatants, tissue homogenates, etc.
- Target species: human, mouse, rabbit, rat, monkey, bovine, etc.
Workflow of KL-6 Detection at Creative BioMart Biomarker
Please feel free to contact us if you would like to know more about KL-6 detection. At Creative BioMart Biomarker, we not only provide high-quality KL-6 detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design the best solution according to your specific requirements.
References:
- Jiang, Y.; et al. Sequential changes of serum KL-6 predict the progression of interstitial lung disease. J Thorac Dis. 2018, 10(8): 4705-4714.
- Ballester, B.; et al. Mucins as a new frontier in pulmonary fibrosis. J Clin Med. 2019, 8: 1447.
